CClinicalTrials.gg
CompletedNCT05240677Updated Jan 5, 2024

Endoscopy in CKD With Iron Deficiency Anemia

An interventional study of Upper GIT endoscopy in Chronic Kidney Diseases and Iron-Deficiency Anemia, sponsored by Walid Ahmed Ragab Abdelhamid. Completed at 1 site in Egypt. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Walid Ahmed Ragab Abdelhamid · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2021, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Iron deficiency anemia is very common in CKD patients. Data about gastrointestinal lesions in Arab patients are insufficient.

Read the detailed description

Iron deficiency anemia without gastrointestinal symptoms needs to be assessed in patients with chronic kidney disease.

02

Conditions studied

03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's enrollment of 81 is above the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

This is the only study on the registry with Walid Ahmed Ragab Abdelhamid as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Patients with eGFR is less than 60 ml/m/1.73 m2.
  • Patients with iron deficiency anemia.
  • Absence of gastrointestinal symptoms.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Placebo comparator
    Group 1

    Chronic kidney diseases patients with iron deficiency anemia and eGFR ≥ 60 ml/min/1.73 m2

    Procedure: Upper GIT endoscopy

  • Experimental
    Group 2

    Chronic kidney diseases patients with iron deficiency anemia and eGFR \< 60 ml/min/1.73 m2.

    Procedure: Upper GIT endoscopy

Interventions

  • ProcedureUpper GIT endoscopy

    Upper gastrointestinal endoscpy for all participants and gastric biopsy for histopathological examination for suspicious lesions

06

What researchers measure

Primary outcomes

  1. Rate of upper gastrointestinal endoscopic findings In chronic kidney disease patients with iron deficiency anemia

    Detect rate of upper GIT lesions in asymptomatic CKD patients with iron deficiency anemia using endoscopy followed by biopsy and histopathological examination

    Time frame: 6 months

07

Study locations

1 site
  • Zagazig university
    Zagazig, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240677
Lead sponsor
Walid Ahmed Ragab Abdelhamid
Responsible party
Walid Ahmed Ragab Abdelhamid (Lecturer internal medicine, Zagazig University) — Sponsor-investigator
First posted
Feb 15, 2022
Start date
May 1, 2021
Primary completion
Mar 15, 2022
Completion
Apr 15, 2022
Last update
Jan 5, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion